Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 162

1.

Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression.

Castagna A, Monno L, Carta S, Galli L, Carrara S, Fedele V, Punzi G, Fanti I, Caramello P, Lepri AC, De Luca A, Ceccherini-Silberstein F, Monforte AD; ICONA Foundation Study Group..

Medicine (Baltimore). 2016 Nov;95(44):e5222.

2.

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district.

Polilli E, Cento V, Restelli U, Ceccherini-Silberstein F, Aragri M, Di Maio VC, Sciacca A, Santoleri F, Fazii P, Costantini A, Perno CF, Parruti G.

Clinicoecon Outcomes Res. 2016 Sep 14;8:467-473.

3.

The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.

Alteri C, Surdo M, Di Maio VC, Di Santo F, Costa G, Parrotta L, Romeo I, Gori C, Santoro MM, Fedele V, Carta S, Continenza F, Pinnetti C, Bellagamba R, Liuzzi G, Orchi N, Latini A, Bertoli A, Girardi E, Alcaro S, Giuliani M, Petrosillo N, Andreoni M, Antinori A, Monforte AD, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V.

J Glob Antimicrob Resist. 2016 Dec;7:1-7. doi: 10.1016/j.jgar.2016.06.005.

PMID:
27530997
4.

Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.

Zaccarelli M, Santoro MM, Armenia D, Borghi V, Gennari W, Gori C, Forbici F, Bertoli A, Fabeni L, Giannetti A, Cicalini S, Bellagamba R, Andreoni M, Mastroianni CM, Mussini C, Ceccherini-Silberstein F, Perno CF, Antinori A.

J Clin Virol. 2016 Sep;82:94-100. doi: 10.1016/j.jcv.2016.07.007.

PMID:
27472519
5.

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.

Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK.

Rev Med Virol. 2016 Nov;26(6):408-434. doi: 10.1002/rmv.1895. Review.

PMID:
27401933
6.

From current status to optimization of HCV treatment: Recommendations from an expert panel.

Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party..

Dig Liver Dis. 2016 Sep;48(9):995-1005. doi: 10.1016/j.dld.2016.06.004.

PMID:
27388261
7.

New findings in HCV genotype distribution in selected West European, Russian and Israeli regions.

Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S; HCV EuResist Study group..

J Clin Virol. 2016 Aug;81:82-9. doi: 10.1016/j.jcv.2016.05.010.

8.

Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.

Armenia D, Di Carlo D, Maffongelli G, Borghi V, Alteri C, Forbici F, Bertoli A, Gori C, Giuliani M, Nicastri E, Zaccarelli M, Pinnetti C, Cicalini S, D'Offizi G, Ceccherini-Silberstein F, Mussini C, Antinori A, Andreoni M, Perno CF, Santoro MM.

HIV Med. 2017 Jan;18(1):21-32. doi: 10.1111/hiv.12388.

PMID:
27353061
9.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group..

J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185.

PMID:
27272727
10.

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord..

J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465.

PMID:
26825119
11.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study..

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8.

PMID:
26762990
12.

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.

Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group..

J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403.

PMID:
26679249
13.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group..

PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877.

14.

Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.

Fokam J, Takou D, Santoro MM, Akonie HZ, Kouanfack C, Ceccherini-Silberstein F, Colizzi V, Perno CF, Ndjolo A.

AIDS Res Hum Retroviruses. 2016 Apr;32(4):329-33. doi: 10.1089/AID.2015.0065.

PMID:
26602836
15.

Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.

Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, Rusconi S, Caramello P, Abrescia N, Mussini C, Monno L, d'Arminio Monforte A; ICONA Foundation Study Group..

Clin Microbiol Infect. 2016 Mar;22(3):288.e1-8. doi: 10.1016/j.cmi.2015.10.026.

PMID:
26551839
16.

May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics.

Tontodonati M, Cento V, Polilli E, Colabattista C, Cascella R, Sciotti M, Di Giammartino D, Trave F, Di Maio VC, Monarca R, Di Candilo F, Prinapori R, Rastrelli E, Vecchiet J, Ceccherini-Silberstein F, Manzoli L, Giardina E, Perno CF, Parruti G.

New Microbiol. 2015 Oct;38(4):491-7.

PMID:
26485008
17.

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Metzner KJ, Paredes R; CHAIN Minority HIV-1 Variants Working group..

Clin Microbiol Infect. 2016 Feb;22(2):191-200. doi: 10.1016/j.cmi.2015.10.004.

PMID:
26482266
18.

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group..

Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5.

PMID:
26424550
19.

Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0.

Surdo M, Bertoli A, Colucci G, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Ciotti M.

Clin Chem Lab Med. 2016 Feb;54(2):e57-9. doi: 10.1515/cclm-2015-0647. No abstract available.

PMID:
26402884
20.

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, Fearnhill E, Marcelin AG, Martinez-Picado J, Kaiser R, Geretti AM; CORONET Study Group..

J Antimicrob Chemother. 2015 Nov;70(11):3080-6. doi: 10.1093/jac/dkv243.

Items per page

Supplemental Content

Loading ...
Support Center